TD Private Client Wealth LLC Sells 7,105 Shares of Eli Lilly and Company (NYSE:LLY)

TD Private Client Wealth LLC reduced its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 56.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,438 shares of the company's stock after selling 7,105 shares during the period. TD Private Client Wealth LLC's holdings in Eli Lilly and Company were worth $4,198,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Highline Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after buying an additional 20 shares in the last quarter. Kovitz Investment Group Partners LLC raised its position in Eli Lilly and Company by 117.1% during the third quarter. Kovitz Investment Group Partners LLC now owns 46,132 shares of the company's stock valued at $41,000 after purchasing an additional 24,879 shares in the last quarter. FPC Investment Advisory Inc. lifted its stake in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares during the last quarter. Compass Financial Services Inc acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $50,000. Finally, Fiduciary Advisors Inc. bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at $58,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. Citigroup reduced their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research note on Tuesday, January 28th. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Finally, Bank of America reiterated a "buy" rating and set a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,009.72.

Remove Ads

Eli Lilly and Company Trading Down 3.0 %

LLY stock traded down $25.51 during trading on Wednesday, hitting $826.84. The company had a trading volume of 2,561,764 shares, compared to its average volume of 3,149,060. The stock has a market cap of $783.98 billion, a PE ratio of 70.61, a PEG ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The business has a 50-day moving average of $839.56 and a 200-day moving average of $837.61.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has authorized a stock repurchase plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's leadership believes its stock is undervalued.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.